|
Re: Novartis Inks Agreement For Immunogen's "TAP" ADC Technology
Excellent news, especially since Novartis has so many breast cancer therapies in the pipeline. Hopefully this will lead to more ADC treatments. Perhaps this time, they can link a less toxic chemo with a MAB and increase both quantity and Quality of life.
|
Linear Mode
